Art. 61 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…

In forcesince 28 Jan 2022cited 10×
1.

Each Member State shall, after consultation of the Management Board, appoint, for a three-year term which may be renewed, one member and one alternate to the Committee for Medicinal Products for Human Use.

The alternates shall represent and vote for the members in their absence and may also be appointed to act as rapporteurs in accordance with Article 62.

Members and alternates shall be chosen for their role and experience in the evaluation of medicinal products for human use as appropriate and shall represent the national competent authorities.

2.

The Committee for Medicinal Products for Human Use may co-opt a maximum of five additional members chosen on the basis of their specific scientific competence. Those members shall be appointed for a term of three years, which may be renewed, and shall not have alternates.

With a view to the co-opting of such members, the Committee for Medicinal Products for Human Use shall identify the specific complementary scientific competence of the additional member or members. Co-opted members shall be chosen among experts nominated by Member States or the Agency.

3.

The members of the Committee for Medicinal Products for Human Use may be accompanied by experts in specific scientific or technical fields.

4.

The Executive Director of the Agency or his or her representative and representatives of the Commission shall be entitled to attend all meetings of the committees referred to in Article 56(1), working parties and scientific advisory groups and all other meetings convened by the Agency or its committees.

5.

In addition to their task of providing objective scientific opinions to the Union and Member States on the questions which are referred to them, the members of the Committee for Medicinal Products for Human Use shall ensure that there is appropriate coordination between the tasks of the Agency and the work of competent national authorities, including the consultative bodies concerned with the marketing authorisation.

6.

Members of the Committee for Medicinal Products for Human Use and experts responsible for evaluating medicinal products shall rely on the scientific evaluation and resources available to national marketing authorisation bodies. Each competent national authority shall monitor the scientific level and independence of the evaluation carried out and facilitate the activities of nominated members of that Committee and experts. Member States shall refrain from giving those members and experts any instruction which is incompatible with their own individual tasks or with the tasks and responsibilities of the Agency.

7.

When preparing the opinion, the committees referred to in Article 56(1) shall use their best endeavours to reach a scientific consensus. If such a consensus cannot be reached, the opinion shall consist of the position of the majority of members and divergent positions, with the grounds on which they are based.

8.

The Committee for Medicinal Products for Human Use shall establish its own rules of procedure.

These rules shall, in particular, lay down:

(a)

procedures for appointing and replacing the Chairman;

(b)

procedures relating to working parties and scientific advisory groups; and

(c)

a procedure for the urgent adoption of opinions, particularly in relation to the provisions of this Regulation on market surveillance and pharmacovigilance.

They shall enter into force after receiving a favourable opinion from the Commission and the Management Board.

  • Judgment of the Court (Fourth Chamber) of 27 March 2019. Dr. August Wolff GmbH & Co. KG Arzneimittel and Remedia d.o.o. v European CommissioDecision

    The Commission challenges the argument that the appointment of Ms W. as rapporteur in a procedure before the Committee initiated by the national authority to which she belongs raised the suspicion, in the light of objective circumstances, …

    27 Mar 2019 · 62016CJ0680

  • Arrêt du Tribunal (cinquième chambre) du 11 décembre 2014. PP Nature-Balance Lizenz GmbH contre Commission européenne.Decision

    … Nach Art. 61 Abs. 7 der Verordnung Nr. 726/2004 nimmt der Ausschuss ein Gutachten mit der Mehrheit seiner Mitglieder an, wenn kein Konsens erreicht werden kann. Wie die Kommission zutreffend vorträgt, führt die bloße Tatsache, dass das …

    11 Dec 2014 · 62013TJ0189

  • Arrêt du Tribunal (cinquième chambre) du 20 octobre 2016. Dr. August Wolff GmbH & Co. KG Arzneimittel et Remedia d.o.o. contre Commission euDecision

    Wie die Kommission hervorgehoben hat, verbietet Art. 61 Abs. 6 der Verordnung Nr. 726/2004 es den Mitgliedstaaten zwar ausdrücklich, „den Ausschussmitgliedern und Sachverständigen Anweisungen zu geben, die mit ihren eigentlichen …

    20 Oct 2016 · 62014TJ0672

  • Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 Decembe…4Law

    … за хуманна употреба, назначени в този комитет в съответствие с член 61, параграф 1 от Регламент (ЕО) № 726/2004. Тези петима членове с …

  • Regulation (EU) 2019/5Lawamends

  • Judgment of the Court (Third Chamber) of 22 June 2023. Federal Republic of Germany v European Commission.Decision

    Title IV of Regulation No 726/2004, entitled ‘The European Medicines Agency – Responsibilities and administrative structure’, includes a Chapter 1, itself entitled ‘Tasks of the agency’, comprising Articles 55 to 66 of that same …

    22 Jun 2023 · 62021CJ0006

  • Arrêt du Tribunal (huitième chambre) du 2 mars 2022. Debregeas et associés Pharma (D & A Pharma) contre Commission européenne et Agence euroDecision

    La requérante estime que, en refusant l’octroi de l’AMM conditionnelle en considérant que « le rapport bénéfice/risque [de l]’Hopveus n’[était] pas favorable », la Commission a entaché la décision attaquée d’une …

    2 Mar 2022 · 62020TJ0556

  • Judgment of the General Court (Fifth Chamber, Extended Composition) of 24 September 2025. Sanofi BV, anciennement Genzyme Europe BV v EuropeDecision

    Second, in accordance with recital 23 and Article 5(2), Article 56(1)(a) and Article 61(7) of Regulation No 726/2004, the ‘exclusive responsibility’ for the preparation of the EMA’s opinions on all questions concerning medicinal …

    24 Sep 2025 · 62022TJ0483

  • Opinion of Advocate General Medina delivered on 7 September 2023. Debregeas et associés Pharma (D & A Pharma) v European Commission and EuroDecision

    Under Article 56(2) of Regulation No 726/2004, the CHMP may establish standing and temporary working parties and also scientific advisory groups in connection with the evaluation of specific types of medicinal products or treatments to …

    7 Sep 2023 · 62022CC0291

  • Opinion of Advocate General Mengozzi delivered on 4 October 2018. Dr. August Wolff GmbH & Co. KG Arzneimittel and Remedia d.o.o. v European Decision

    The Commission challenges the argument that the appointment of the German member of the CHMP as rapporteur in a procedure initiated by the Federal Republic of Germany before the CHMP raises the suspicion, in the light of objective …

    4 Oct 2018 · 62016CC0680